BlackRock
DYN icon

BlackRock’s Dyne Therapeutics DYN Stock Holding History

BlackRock’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276M Buy
12,404,330
+704,460
+6% +$13.1M ﹤0.01% 1597
2026
Q1 		$212M Buy
11,699,870
+509,032
+5% +$8.78M ﹤0.01% 1636
2025
Q4 		$219M Buy
11,190,838
+1,555,929
+16% +$29.5M ﹤0.01% 1619
2025
Q3 		$122M Buy
9,634,909
+1,556,481
+19% +$17.8M ﹤0.01% 1980
2025
Q2 		$76.9M Buy
8,078,428
+31,490
+0.4% +$347K ﹤0.01% 2218
2025
Q1 		$84.2M Buy
8,046,938
+97,536
+1% +$1.4M ﹤0.01% 2102
2024
Q4 		$187M Buy
7,949,402
+155,288
+2% +$4.59M ﹤0.01% 1712
2024
Q3 		$280M Buy
7,794,114
+407,126
+6% +$16.2M 0.01% 1460
2024
Q2 		$261M Buy
7,386,988
+1,996,946
+37% +$58M 0.01% 1439
2024
Q1 		$153M Buy
5,390,042
+1,601,360
+42% +$36.2M ﹤0.01% 1811
2023
Q4 		$50.4M Buy
3,788,682
+481,717
+15% +$4.71M ﹤0.01% 2465
2023
Q3 		$29.6M Sell
3,306,965
-15,222
-0.5% -$164K ﹤0.01% 2708
2023
Q2 		$37.4M Buy
3,322,187
+702,966
+27% +$8.29M ﹤0.01% 2663
2023
Q1 		$30.2M Buy
2,619,221
+603
+0% +$7.83K ﹤0.01% 2758
2022
Q4 		$30.3M Buy
2,618,618
+93,551
+4% +$1.08M ﹤0.01% 2800
2022
Q3 		$32.1M Buy
2,525,067
+50,569
+2% +$580K ﹤0.01% 2757
2022
Q2 		$17M Buy
2,474,498
+109,517
+5% +$754K ﹤0.01% 3171
2022
Q1 		$22.8M Sell
2,364,981
-46,416
-2% -$395K ﹤0.01% 3094
2021
Q4 		$28.7M Buy
2,411,397
+423,245
+21% +$5.95M ﹤0.01% 3042
2021
Q3 		$32.3M Buy
1,988,152
+15,944
+0.8% +$283K ﹤0.01% 2954
2021
Q2 		$41.5M Buy
1,972,208
+730,497
+59% +$13.7M ﹤0.01% 2823
2021
Q1 		$19.3M Buy
1,241,711
+205,594
+20% +$3.98M ﹤0.01% 3205
2020
Q4 		$21.8M Buy
1,036,117
+732,117
+241% +$14.5M ﹤0.01% 2963
2020
Q3 		$6.14M Buy
+304,000
New +$6.67M ﹤0.01% 3482

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock's DYN Position: Q2 2026 in Review

BlackRock increased its Dyne Therapeutics (DYN) stake by 6% in Q2 2026, buying an estimated $13.1M and bringing the position to 12,404,330 shares worth $276M. The position accounts for ﹤0.01% of the portfolio, ranked #1597.

BlackRock first reported a position in DYN in Q3 2020 and has held it in 24 quarters since. The position peaked at $280M in Q3 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • BlackRock held 12,404,330 shares of Dyne Therapeutics worth $276M as of Q2 2026.
  • BlackRock bought 704,460 Dyne Therapeutics shares in Q2 2026, an estimated $13.1M.
  • Dyne Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1597 holding.
  • BlackRock first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • BlackRock's Dyne Therapeutics position peaked at $280M in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.